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Abstract
Alpha-1-antitrypsin (A1AT) deficiency is a genetic disease characterized by low levels and/or function of A1AT
protein. A1AT deficiency can result in the development of COPD, liver disease, and certain skin conditions. The
disease can be diagnosed by demonstrating a low level of A1AT protein and genotype screening for S and Z
mutations, which are the most common. However, there are many genetic variants in A1AT deficiency, and this
screening may miss rarer cases, such as those caused by dysfunctional protein. We identified a patient with a
previously unreported F/null phenotype that was missed by routine screening. This case highlights the wide
variation in possible mutations, limitations in diagnostics, and the importance of combining clinical suspicion with
measurement of protein levels, phenotypic analysis, and in appropriate cases expanded genetic analysis.
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Background
Alpha-1 Antitrypsin (A1AT) is a serine protease inhibitor
that is encoded by the SERPINA 1 gene located on chro-
mosome 14 [1,2]. It is a highly effective inhibitor of neu-
trophil elastase, and serves a protective function to
prevent excessive proteolysis of matrix components in the
airways and other organs [1,2]. A wide variety of muta-
tions in the SERPINA1 gene are possible, and these can
result in low/absent levels or non-functional protein [1-3].
A1AT deficiency results in early onset emphysema, and
may induce liver disease, necrotizing panniculitis, or a C-
ANCA positive vasculitis [1,2].
A1AT deficiency is most often seen in a population of
European origin, but can affect all races [3]. It is esti-
mated that in the United States there is 1 case per 3000-
5000 persons, though the carrier frequency of mutant
alleles has been reported to be 2-3% of the American
population, suggesting that the prevalence may be higher
than this [1-3]. It is also estimated that only about 10% of
the patients with this condition are currently identified,
due in part to low recognition of the disease, genetic het-
erogeneity, and complexities of diagnosis [1-3].
The normal A1AT gene product is designated Pi*M, and
there more than 100 known variants [1]. The most com-
mon mutant alleles are Pi*Z and Pi*S, and inheritance of
these as homozygous alleles (i.e. Pi*ZZ, Pi*SS) or com-
pound heterozygotes (Pi*SZ) results in a deficiency
state [1-3]. These mutations are characterized by low levels
and dysfunction of A1AT. Rare null mutations result in
completely absent protein, and others, such as F, confer
dysfunctional protein with normal levels [4-6]. Available
diagnostic tests include measurement of protein levels,
genotyping for common mutations, or phenotypic analysis
of variants by isoelectric focusing (IEF) [7]. However, given
the wide spectrum of mutations, diagnosis can be challen-
ging and use of any of these tests alone can be misleading.
We present an A1AT-deficient patient with a novel and
previously undescribed F/null phenotype who was initially
misdiagnosed based on protein level and genotyping. This
case highlights the genetic heterogeneity of the disease
and complexities in diagnosis of A1AT deficiency.
Case Report
The patient is a 64 year old male who was seen with a
chief complaint of dyspnea and recurrent skin rash. His
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dyspnea had been persistent and worsening in nature
since he was diagnosed with COPD at age 49. Treat-
ment with fluticasone 220 mcg 2 puffs twice a day via a
HFA inhaler did not provide benefit, and he required
use of albuterol as a rescue inhaler multiple times per
week. He had a 10 pack-year history of cigarette-smok-
ing, but stopped 7 years ago. His rash was described as
diffuse, pruritic, erythematous, and raised, consistent
with urticaria. It started approximately eight months ago
and presented multiple times per week. Treatment with
antihistamines (cetirizine 10 mg daily, hydroxyzine 50
mg every 6 hours as needed) and prednisone 40 mg
daily were both ineffective. There were no known trig-
gers and no implicated drugs or foods. His past medical
history was otherwise significant only for chronic rhini-
tis. He had no history of liver disease or vasculitis.
Review of systems was unremarkable. There was
no family history of lung disease, liver disease, or
autoimmunity.
Medications at presentation included cetirizine 10 mg
daily, fluticasone HFA 220 mcg, two puffs twice a day,
albuterol HFA as needed, mometasone nasal spray and
azelastine nasal spray.
Physical examination revealed bilateral wheezing and a
generalized erythematous, maculopapular rash predomi-
nantly on the torso and arms. The remainder of the phy-
sical exam was otherwise unremarkable. He previously
had numerous blood tests performed, including LFTs,
CBC, Hepatitis serologies, HIV screening, TSH, Free T4,
ANA CH50, ANCA and CRP, which were all within nor-
mal limits.
Pulmonary function testing revealed an FEV1 of 1.82
L (52% of predicted) with an FEV1/FVC ratio of 70%.
He failed to demonstrate significant reversibility with
albuterol treatment, (post-bronchodilator increase in
FEV1 of 9%). He was found to have a reduced DLCO of
17.73 ml/min/mmHg (62% of predicted), and evidence
of air trapping with a RV of 3.26 L (127% of predicted).
The latter may have led to an artifactually low FVC
resulting in an FEV1/FVC ratio that was only mildly
decreased. His pulmonary function tests over the past
four years were also reviewed, which showed a 24.7%
decrease in FEV1 over that time period, despite treat-
ment with inhaled corticosteroids and long acting
bronchodilators.
A skin biopsy was performed on an urticarial lesion,
which showed a perivascular infiltration of mostly neu-
trophils without any evidence of blood vessel damage,
consistent with a neutrophil-predominant urticaria.
Given the poor response to treatment and the early
onset of COPD with a minimal smoking history, the diag-
nosis of A1AT deficiency was considered. Serum testing
for A1AT revealed a borderline-low level of 93 mg/dL
(normal range is 100-190 mg/dL). A genotype analysis
was performed at a commercial laboratory, which was
reported as a normal MM genotype.
Because of the clinical history of COPD and a discre-
pancy between the low A1AT serum levels and reported
MM genotype, we remained suspicious that the patient
could have a functional A1AT deficiency and performed a
phenotype analysis. Isoelectric focusing (Figure 1A) indi-
cated the presence of an F phenotype, and based on the
low A1AT level, it was suspected that this represented an
F/null phenotype. The F/null phenotype is extremely rare,
and would be missed by the commercial genotype screen,
which probes the most common mutations, S and Z. In
these cases, the result may be reported by default as MM.
To confirm the patient’s F genotype, we sequenced the
A1AT gene in our research laboratory. As shown in
Figure 1B, we demonstrated that one allele harbored a
T/C single nucleotide polymorphism (SNP) at nucleotide
739 in exon 4 of the A1AT gene, resulting in an Arg to
Cys change (R247C). This mutation has previously been
described to confer an F phenotype, consistent with the
IEF analysis [4,5]. This is a rare mutation that results in
production of a dysfunctional protein, usually with nor-
mal levels.
As the 739 T/C mutation was present in only one
allele and only F bands were observed on IEF, we
hypothesized that the patient’s phenotype was F/null
and sequenced the rest of the A1AT gene. Amplification
of exon 5 of the A1AT gene from genomic DNA and
sequencing of the PCR-product suggested that there was
a heterozygous frameshift at nucleotide 1158. To further
analyze this, the PCR products were cloned into a
TOPO2.1 vector and sequenced. As expected, we
observed insertion of a C at nucleotide 1158 in approxi-
mately half of the samples screened and the normal
sequence in the others, indicating heterozygosity (Figure
1C, D). The 1158 C insertion results in a frameshift that
changes crucial amino acids in the active site at the C-
terminus of the protein and introduces a premature
stop codon after amino acid 399. This mutation has not
been described, but is similar in nature to the rare Null
Bolton mutation, which arises from a deletion of a C at
the same position and also produces a frameshift with a
premature stop codon [6,8].
The F mutation produces in a protein that lacks activ-
ity, such that patients with homozygous F/F phenotypes
develop A1AT deficiency despite having normal protein
levels [4,5]. Our patient was a compound F/null hetero-
zygote, and thus would be expected to produce reduced
levels of A1AT protein that had reduced function. Com-
plicating the diagnosis, however, was that the A1AT
protein level was only slightly decreased at 93 mg/dL,
the lower limit being 100 mg/dL. Thus, clinical suspi-
cion and further phenotype testing and gene sequencing
was needed to establish the diagnosis.
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This case of A1AT deficiency highlights the variability of
possible mutations, and raises a number of questions
related to diagnosis of the disease. A1AT deficiency should
be considered in all cases of COPD, especially so in
patients without a significant history of smoking, in young
patients, and in patients with asthma when significant
obstruction persists after treatment. In this case in particu-
lar, our patient demonstrated a 25% decrease in FEV1 over
the span of four years, which increased our suspicion of
the disease.
However, given the large number of potential muta-
tions, diagnosis of A1AT deficiency can be challenging.
In this patient, we had a high index of suspicion for
A1AT deficiency, but a protein level was only slightly
below the lower limit of normal and genotyping was
reported as MM. Measurement of A1AT levels alone can
be misleading. First of all, A1AT is an acute phase reac-
tant and levels can vary from depending on many factors
and from one blood draw to another [1]. Secondly, in
cases such as F/F phenotypes, the A1AT level will be nor-
mal, thought the protein is dysfunctional. Furthermore,
the range of normal levels of A1AT is quite broad, the
lower limit may vary by lab (as low as 90 mg/dL), and
even patients with low normal or normal levels by report
may be deficient.
Thus, low levels of A1AT should prompt further investi-
gation and further evaluation by phenotypic analysis. Not







































Figure 1 Identification of the patient’s phenotype and genotype. A, Determination of phenotype by IEF of A1AT isotypes in the patient and
controls. Comparison of the patient’s sample with controls of the M/M, M/F, and M/Z phenotype revealed that the patient’s serum contained
only F bands (M, F, Z bands indicated by labels on gel). B, DNA sequencing of exon 4 demonstrated a T/C SNP at nucleotide 739 (R247C). C,
sequencing of exon 5 showed the presence of a normal allele (C) and a C insertion at nucleotide 1158 (D).
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analysis in cases where the A1AT level is low, so the phy-
sician ordering the tests should keep this in mind. How-
ever, even when levels are normal, if there is clinical
suspicion, phenotypic analysis is warranted to diagnosis
deficiency due to dysfunctional protein.
Genotype testing at most commercial labs utilize probes
to the most common mutations, and combined with
A1AT levels may also be used to screen for A1AT defi-
ciency. However, this may miss rare mutations (as in our
case), and it is important to note that although a genotype
may be reported as MM, it may rather reflect an absence
of the most common S and Z mutations. In fact, we would
argue that all labs that utilize PCR to probe for these two
mutations should report the results in this manner to
reduce confusion. More extensive gene sequencing may be
necessary in select cases to indentify rare mutations. In
any case, the clinical history, A1AT level measurement,
phenotype analysis, and genotyping should be used in con-
cert, and physicians should be aware of limitations of each
of the diagnostics tests.
Our patient was started on A1AT replacement therapy
and has had no further decline in his lung function or
worsening of symptoms, though long term monitoring of
lung function is needed to determine if treatment will
slow the rate of FEV1 decline. The neutrophilic urticaria
was treated with plaquenil 200 mg twice a day, and symp-
toms have improved. It is not clear if urticaria is a unique
finding related to this specific mutation, though a neutro-
philic panniculitis has been described in A1AT defi-
ciency [9]. This panniculitis tends to present similarly to
cellulitis and has been described in patients with heterozy-
gous and homozygous mutations, but not in patients with
the F phenotype [10].
Conclusions
We present a patient with A1AT whose diagnosis was
delayed secondary to the presence of a rare mutation and
A1AT level just below normal limits. The case emphasizes
the importance of maintaining a high level of suspicion for
disease in patients with COPD, and reinforces the utility
of A1AT screening in these patients as this disease is
under-diagnosed. This case supports an algorithm of
screening that includes measuring an A1AT level, followed
by genotyping and phenotypic assays. The limitations of
each should be considered, and in some cases more exten-
sive gene sequencing may be necessary to confirm the
genotype.
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